Primary cultured adipocytes for gene therapy
The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo gene therapy. The present invention established methods for transferring foreign genes into primary cultured adipocytes, which are suitable for ex vivo gene therapy; can be easily collected and implanted; and can be removed after implantation. Specifically, the present invention established these methods that use retroviral vectors. The present invention also established primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells.
1. A population of primary cultured preadipocytes, wherein the preadipocytes are isolated and established from adipose tissue and stably maintain a foreign DNA encoding a protein that is secreted outside of a cell, and wherein the DNA is operably linked to a promoter sequence, wherein the population of primary cultured preadipocytes express the protein encoded by the foreign DNA for about one year in vivo when transplanted in a recipient host.
2. The preadipocyte population of claim 1 , wherein the DNA is transferred to the cell by a retroviral vector or adeno-associated viral vector.
3. The preadipocyte population of claim 1 , which is used to release the protein into the blood flow of said host.
4. The preadipocyte population of claim 1 , wherein the protein is insulin or glucagon-like peptide 1 (GLP-1).
5. A method of producing a population of primary cultured preadipocytes, wherein the method comprises the steps of:
(1) isolating cells from adipose tissue and establishing a primary culture of preadipocytes; and
(2) transferring into the preadipocytes a foreign DNA operably linked to a promoter sequence and encoding a protein that is secreted outside of the cell and then stably maintaining the foreign DNA in the genome of the preadipocytes, wherein the population of primary cultured preadipocytes express the protein encoded by the foreign DNA for about one year in vivo when transplanted in a recipient host.
6. The method of claim 5 , wherein the foreign gene is transferred by a retroviral vector or adeno-associated viral vector.
7. A population of primary cultured preadipocytes, which is produced by the method of claim 5 .
8. An implant composition for gene therapy, wherein the composition comprises a population of primary cultured preadipocytes, which are isolated and established from adipose tissue and stably maintain in the genome a foreign DNA encoding a protein that is secreted outside of the cell, and a pharmaceutically acceptable carrier, wherein the DNA is operably linked to a promoter sequence, wherein the population of primary cultured preadipocytes express the protein encoded by the foreign DNA for about one year in vivo when transplanted in a recipient host.
9. The implant composition of claim 8 , which further comprises an extracellular matrix component.
10. The implant composition of claim 8 , which further comprises an angiogenesis factor.
11. A population of primary cultured preadipocytes, which is produced by the method of claim 6 .
12. A population of primary cultured preadipocytes, wherein the preadipocytes are isolated and established from adipose tissue and stably maintain a foreign DNA encoding a protein that is secreted outside of a cell, wherein the DNA is operably linked to a promoter sequence, wherein the population of primary cultured preadipocytes express the protein encoded by the foreign DNA for about one year in vivo when transplanted in a recipient host, and wherein the population is obtained by ceiling culture.
13. The method of claim 5 , wherein the primary culture is established in step (1) by ceiling culture.